Metastatic hidradenocarcinoma with demonstration of Her-2/neu gene amplification by fluorescence in situ hybridization: Potential treatment implications

Journal of Cutaneous Pathology

Volumn 34, Issue 1, 2007, Pages 49-54

  Nash, Jason W ^a   Barrett, Terry L ^b   Kies, Merrill ^a   Ross, Merrick I ^a   Sneige, Nour ^a   Diwan, A Hafeez ^a   Lazar, Alexander J F ^a  

^a UNIVERSITY OF TEXAS   (United States)

^b UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANDROGEN RECEPTOR; CARCINOEMBRYONIC ANTIGEN; CYTOKERATIN; CYTOKERATIN 5; CYTOKERATIN 7; ESTROGEN RECEPTOR; MAMMOGLOBULIN; MUCIN 2; MUCIN 5AC; PROTEIN; PROTEIN P53; PROTEIN P63; PROTEIN S 100; THYROID TRANSCRIPTION FACTOR 1; TRANSCRIPTION FACTOR CDX2; TRASTUZUMAB; UNCLASSIFIED DRUG; VILLIN;

ADULT; ARTICLE; AXILLA; CANCER ADJUVANT THERAPY; CANCER RADIOTHERAPY; CASE REPORT; CLINICAL FEATURE; FLUORESCENCE IN SITU HYBRIDIZATION; GENE AMPLIFICATION; HUMAN; IMMUNOHISTOCHEMISTRY; LYMPHADENOPATHY; MALE; METASTASIS; ONCOGENE NEU; RADIOGRAPHY; STATISTICAL SIGNIFICANCE; SWEAT GLAND CARCINOMA;

ADENOMA, SWEAT GLAND; ADULT; ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC AGENTS; AXILLA; GENE AMPLIFICATION; GENES, ERBB-2; HUMANS; IMMUNOHISTOCHEMISTRY; IN SITU HYBRIDIZATION, FLUORESCENCE; LYMPH NODE EXCISION; LYMPHATIC METASTASIS; MALE; RADIOTHERAPY, ADJUVANT; SWEAT GLAND NEOPLASMS; THORACIC WALL;

EID: 33846084709     PISSN: 03036987     EISSN: 16000560     Source Type: Journal    
DOI: 10.1111/j.1600-0560.2006.00570.x     Document Type: Article

References (30)

1. McKee PH, Calonje E, Granter SR. Pathology of the skin, 3rd ed. Philadelphia: Elsevier, 2005.
2. Morris DM, Sanusi ID, Lanehart WH. Carcinoma of eccrine sweat gland: experience with chemotherapy, autopsy findings in a patient with metastatic eccrine carcinoma, and a review of the literature. J Surg Oncol 1986; 31: 26.
3. Hopman AH, Ramaekers FC, Raap AK, et al. In situ hybridization as a tool to study numerical chromosome aberrations in solid bladder tumors. Histochemistry 1988; 89: 307.
4. Messing MJ, Richardson MS, Smith MT, King L, Gallup DG. Metastatic clear-cell hidradenocarcinoma of the vulva. Gynecol Oncol 1993; 48: 264.
5. Mirza I, Kloss R, Sieber SC. Malignant eccrine spiradenoma. Arch Pathol Lab Med 2002; 126: 591.
6. Elder DE, Elenitsas R, Johnson BL, Murphy GF. Histopathology of the skin, 9th ed. Philadelphia: Lippincott Williams & Wilkins, 2005.
7. Bogner PN, Fullen DR, Lowe L, et al. Lymphatic mapping and sentinel lymph node biopsy in the detection of early metastasis from sweat gland carcinoma. Cancer 2003; 97: 2285.
8. Michl C, Starz H, Bachter D, Balda BR. Sentinel lymphadenectomy in nonmelanoma skin malignancies. Br J Dermatol 2003; 149: 763.
9. Briscoe KE, Grage T, Kennedy BJ. Sustained complete remission of metastatic sweat gland carcinoma following regional hyperthermic perfusion. JAMA 1978; 240: 51.
10. el-Domeiri AA, Brasfield RD, Huvos AG, Strong EW. Sweat gland carcinoma: a clinico-pathologic study of 83 patients. Ann Surg 1971; 173: 270.
11. Hirsh LF, Enterline HT, Rosato EF, Rosato FE. Sweat gland carcinoma. Ann Surg 1971; 174: 283.
12. Sridhar KS, Benedetto P, Otrakji CL, Charyulu KK. Response of eccrine adenocarcinoma to tamoxifen. Cancer 1989; 64: 366.
13. Schroder U, Dries V, Klussmann JP, Wittekindt C, Eckel HE. Successful adjuvant tamoxifen therapy for estrogen receptor-positive metastasizing sweat gland adenocarcinoma: need for a clinical trial? Ann Otol Rhinol Laryngol 2004; 113 (3 Pt 1): 242.
14. Daniel SJ, Nader R, Kost K, Huttner I. Facial sweat gland carcinoma metastasizing to neck nodes: a diagnostic and therapeutic challenge. Arch Otolaryngol Head Neck Surg 2001; 127: 1495.
15. Wick MR, Ockner DM, Mills SE, Ritter JH, Swanson PE. Homologous carcinomas of the breasts, skin, and salivary glands. A histologic and immunohistochemical comparison of ductal mammary carcinoma, ductal sweat gland carcinoma, and salivary duct carcinoma. Am J Clin Pathol 1998; 109: 75.
16. Wallace ML, Longacre TA, Smoller BR. Estrogen and progesterone receptors and anti-gross cystic disease fluid protein 15 (brst-2) fail to distinguish metastatic breast carcinoma from eccrine neoplasms. Mod Pathol 1995; 8: 897.
17. Busam KJ, Tan LK, Granter SR, et al. Epidermal growth factor, estrogen, and progesterone receptor expression in primary sweat gland carcinomas and primary and metastatic mammary carcinomas. Mod Pathol 1999; 12: 786.
18. Swanson PE, Mazoujian G, Mills SE, Campbell RJ, Wick MR. Immunoreactivity for estrogen receptor protein in sweat gland tumors. Am J Surg Pathol 1991; 15: 835.
19. Wick MR, Swanson PE, Kaye VN, Pittelkow MR. Sweat gland carcinoma ex eccrine spiradenoma. Am J Dermatopathol 1987; 9: 90.
20. Hasebe T, Mukai K, Ishihara K, Kaneko A, Shimosato Y. Sebaceous gland and sweat gland carcinomas of the skin. Clinicopathological study and significance of c-erbb-2 oncoprotein expression. Acta Pathol Jpn 1992; 42: 585.
21. Hasebe T, Mukai K, Yamaguchi N, et al. Prognostic value of immunohistochemical staining for proliferating cell nuclear antigen, p53, and c-erbb-2 in sebaceous gland carcinoma and sweat gland carcinoma: comparison with histopathological parameters. Mod Pathol 1994; 7: 37.
22. Ross JS, Fletcher JA, Linette GP, et al. The her-2/neu gene and protein in breast cancer 2003: biomarker and target of therapy. Oncologist 2003; 8: 307.
23. Cho KJ, Khang SK, Koh JS, Chung JH, Lee SS. Sebaceous carcinoma of the eyelids: frequent expression of c-erbb-2 oncoprotein. J Korean Med Sci 2000; 15: 545.
24. Krahn G, Leiter U, Kaskel P, et al. Coexpression patterns of egfr, her2, her3 and her4 in non-melanoma skin cancer. Eur J Cancer 2001; 37: 251.
25. Bodey B, Bodey B Jr, Groger AM, et al. Clinical and prognostic significance of the expression of the c-erbb-2 and c-erbb-3 oncoproteins in primary and metastatic malignant melanomas and breast carcinomas. Anticancer Res 1997; 17: 1319.
26. Stern DF, Heffernan PA, Weinberg RA. P185, a product of the neu proto-oncogene, is a receptor-like protein associated with tyrosine kinase activity. Mol Cell Biol 1986; 6: 1729.
27. Baselga J, Albanell J. Mechanism of action of anti-her2 monoclonal antibodies. Ann Oncol 2001; 12 (Suppl. 1): S35.
28. Sliwkowski MX, Lofgren JA, Lewis GD, et al. Nonclinical studies addressing the mechanism of action of trastuzumab (herceptin). Semin Oncol 1999; 26 (4 Suppl. 12): 60.
29. Rueckert S, Ruehl I, Kahlert S, Konecny G, Untch M. A monoclonal antibody as an effective therapeutic agent in breast cancer: trastuzumab. Expert Opin Biol Ther 2005; 5: 853.
30. Hanrahan EO, Hennessy BT, Valero V. Neoadjuvant systemic therapy for breast cancer: an overview and review of recent clinical trials. Expert Opin Pharmacother 2005; 6: 1477.